In contrast, interventions that reduce circulating IgG, such as neonatal Fc receptor (FcRn) antagonists, or deplete B cells, target the autoantibody axis more broadly and can also benefit IgG4-mediated forms such as MuSK-positive MG. This evidence concerns the gene MUSK and myasthenia gravis.